About this episode
Pursuing social anxiety disorder with MDMA. Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences , a biotech company focused on mental health and psychedelic compounds (1:30). Standing on the shoulders of Johnson & Johnson's Spravato (4:00). Upcoming milestones and clinical trials (13:15). Psychedelic industry sentiment; RFK Jr influence (30:40). Show Notes: Psychedelic Stocks: Focus On Their Cash Deep Dive: Atai Life Sciences FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged Read our episode transcripts For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions